• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Transplantation - Pipeline Review, H2 2012 Product Image

Transplantation - Pipeline Review, H2 2012

  • ID: 2233973
  • August 2012
  • 291 pages
  • Global Markets Direct

Transplantation – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Transplantation - Pipeline Review, H2 2012', provides an overview of the Transplantation therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. 'Transplantation - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Transplantation.
- A review of the Transplantation products under development by companies and universities/research institutes based on READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 7
List of Figures 11
Introduction 12
REPORT COVERAGE 12
Transplantation Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Transplantation 14
Transplantation Therapeutics under Development by Companies 16
Transplantation Therapeutics under Investigation by Universities/Institutes 24
Late Stage Products 31
Comparative Analysis 31
Mid Clinical Stage Products 32
Comparative Analysis 32
Early Clinical Stage Products 33
Comparative Analysis 33
Discovery and Pre-Clinical Stage Products 34
Comparative Analysis 34
Transplantation Therapeutics – Products under Development by Companies 35
Transplantation Therapeutics – Products under Investigation by Universities/Institutes 44
Companies Involved in Transplantation Therapeutics Development 57
Genzyme Corporation 57
Kyowa Hakko Kirin Co., Ltd. 58
Osiris Therapeutics, Inc. 59
Amgen Inc. 60
Athersys, Inc. 61
GlaxoSmithKline plc 62
Quark Pharmaceuticals, Inc. 63
AbGenomics International, Inc. 64
Emergent BioSolutions Inc. 65
Oxford BioMedica plc 66
Pharming Group N.V. 67
Albany Molecular Research, Inc. 68
Vectura Group plc 69
BioLineRx, Ltd. 70
Novartis AG 71
Isotechnika Pharma Inc. 72
Astellas Pharma Inc. 73
Pfizer Inc. 74
Rigel Pharmaceuticals, Inc. 75
ViroPharma Incorporated 76
Genmab A/S 77
novosom AG 78
Zosano Pharma, Inc. 79
4SC AG 80
Celldex Therapeutics, Inc. 81
IMMUNOMEDICS, INC 82
LifeCycle Pharma A/S 83
Circadian Technologies Limited 84
Cleveland BioLabs, Inc. 85
Clinuvel Pharmaceuticals Limited 86
Accentia Biopharmaceuticals, Inc. 87
La Jolla Pharmaceutical Company 88
Jazz Pharmaceuticals, Inc. 89
Alexion Pharmaceuticals, Inc. 90
Portola Pharmaceuticals, Inc. 91
Soligenix, Inc. 92
NeoStem, Inc. 93
Cytomedix, Inc. 94
JCR Pharmaceuticals Co., Ltd. 95
Pluristem Therapeutics Inc. 96
MediPost Co., Ltd. 97
Proteo, Inc. 98
Cellerant Therapeutics, Inc. 99
Digna Biotech, S.L. 100
Biotecnol SA 101
Viron Therapeutics, Inc. 102
Pharmalink AB 103
Wellstat Therapeutics Corporation 104
Argos Therapeutics, Inc. 105
Cytheris SA 106
APT Pharmaceuticals, Inc. 107
Alder Biopharmaceuticals Inc. 108
Gene Signal International SA. 109
Recoly N.V. 110
Opsona Therapeutics Ltd. 111
TetraLogic Pharmaceuticals 112
Fresenius Biotech GmbH 113
Conatus Pharmaceuticals Inc. 114
Angion Biomedica Corp. 115
NovImmune SA 116
Lumen Therapeutics 117
TcL Pharma SAS 118
Polyphor Ltd. 119
Omeros Corporation 120
Adeona Pharmaceuticals, Inc. 121
Trillium Therapeutics Inc. 122
iBio, Inc. 123
Kiadis Pharma B.V. 124
CBio Limited 125
Bellicum Pharmaceuticals, Inc. 126
Sirnaomics, Inc. 127
Limerick BioPharma, Inc. 128
Biokine Therapeutics Ltd. 129
KYORIN Pharmaceutical Co., Ltd. 130
Tolera Therapeutics, Inc. 131
Medistem, Inc. 132
NasVax Ltd. 133
Ikaria Inc. 134
REGiMMUNE Corporation 135
ADIENNE Pharma & Biotech 136
TikoMed AB 137
Nephrx Corporation 138
Dr. Falk Pharma GmbH 139
Dompe Farmaceutici S.p.A. 140
Amplimmune, Inc. 141
Lycera Corp. 142
Perseid Therapeutics LLC 143
ImmuneWorks, LLC 144
RNL BIO Co., Ltd. 145
Icon Bioscience, Inc. 146
Therapure Biopharma Inc. 147
Neumedicines Inc. 148
iTherX Pharmaceuticals Inc. 149
Sigmoid Pharma. 150
Biopeutics co., Ltd. 151
Transplantation – Therapeutics Assessment 152
Assessment by Monotherapy Products 152
Assessment by Combination Products 153
Assessment by Route of Administration 154
Assessment by Molecule Type 156
Drug Profiles 159
Prochymal - Drug Profile 159
Sensipar - Drug Profile 161
ATIR - Drug Profile 163
orBec - Drug Profile 164
Voclosporin - Drug Profile 166
Pulminiq - Drug Profile 168
Leukotac - Drug Profile 170
Mycophenolate + Corticosteroids - Drug Profile 171
GS-101 - Drug Profile 172
Prograf + Methotrexate - Drug Profile 174
Prograf - Drug Profile 175
Thymoglobulin + Cellcept + Certican+ Corticosteroids - Drug Profile 176
Simulect + Cellcept + Neoral + Certican + Corticosteroids - Drug Profile 178
Prevnar - Drug Profile 180
Simulect - Drug Profile 182
Budesonide - Drug Profile 183
Captopril - Drug Profile 185
Enbrel - Drug Profile 186
ATG-Fresenius S - Drug Profile 187
Advagraf + Mycophenolate Mofetil - Drug Profile 189
Advagraf + Mycophenolate Mofetil + Basiliximab - Drug Profile 190
Papeilin - Drug Profile 192
fluconazole - Drug Profile 193
Rituximab - Drug Profile 194
N-Acetylcysteine - Drug Profile 196
Rapamycin - Drug Profile 197
Mycophenolate Mofetil - Drug Profile 198
Tacrolimus + Steroid - Drug Profile 200
Tacrolimus + Mycophenolate Mofetil - Drug Profile 201
Campath-1H + Sirolimus - Drug Profile 202
Campath-1H + Tacrolimus - Drug Profile 203
Legalon SIL - Drug Profile 204
Varivax - Drug Profile 205
Busulfan + Fludarabine + Anti-Thymocyte Globulin + Stem Cell Transplant + Total Lymphoid Irradiation - Drug Profile 206
Sirolimus - Drug Profile 208
Thymoglobulin - Drug Profile 209
Tacrolimus + Sirolimus - Drug Profile 211
Cyclosporine - Drug Profile 212
Tacrolimus - Drug Profile 213
LCP-Tacro - Drug Profile 214
Methotrexate + Tacrolimus - Drug Profile 216
Pentostatin + Tacrolimus + Sirolimus + Cyclophosphamide - Drug Profile 217
Cyclophosphamide + Fludarabine + Anti Thymocyte Globulin - Drug Profile 219
Flu-ATG - Drug Profile 221
Anti-CD 25 mAb + Sirolimus + MMF - Drug Profile 222
Sirolimus + Extracorporeal Photopheresis + Prednisone - Drug Profile 224
Anti R-IL2 + Cyclosporine + Everolimus - Drug Profile 226
Thymoglobulin + Everolimus - Drug Profile 228
Rituximab - Drug Profile 230
Aldesleukin + Recombinant Interferon Gamma + Busulfan + Cyclophosphamide + Cyclosporine + Radiation Therapy - Drug Profile 231
Methotrexate + Cyclosporine A - Drug Profile 233
Alefacept - Drug Profile 234
Daclizumab - Drug Profile 235
Methotrexate + Sirolimus + Tacrolimus - Drug Profile 236
Methotrexate + Tacrolimus + Sirolimus + Cyclophosphamide - Drug Profile 238
Thymoglobulin - Drug Profile 240
Afinitor + Tacrolimus - Drug Profile 241
Sirolimus + Prednisone - Drug Profile 243
Advagraf + Mycophenolate Mofetil + Methylprednisolone - Drug Profile 245
Allogenic Mesenchymal Stem Cells - Drug Profile 247
Transplantation Therapeutics – Drug Profile Updates 249
Transplantation Therapeutics – Discontinued Products 260
Transplantation Therapeutics - Dormant Products 264
Transplantation – Product Development Milestones 278
Featured News & Press Releases 278
Appendix 286
Methodology 286
Coverage 286
Secondary Research 286
Primary Research 286
Expert Panel Validation 286
Contact Us 287
Disclaimer 287

List of Tables
Number of Products Under Development for Transplantation, H2 2012 18
Products under Development for Transplantation – Comparative Analysis, H2 2012 19
Number of Products under Development by Companies, H2 2012 21
Number of Products under Development by Companies, H2 2012 (Contd..1) 22
Number of Products under Development by Companies, H2 2012 (Contd..2) 23
Number of Products under Development by Companies, H2 2012 (Contd..3) 24
Number of Products under Development by Companies, H2 2012 (Contd..4) 25
Number of Products under Development by Companies, H2 2012 (Contd..5) 26
Number of Products under Development by Companies, H2 2012 (Contd..6) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 34
Comparative Analysis by Late Stage Development, H2 2012 35
Comparative Analysis by Mid Clinical Stage Development, H2 2012 36
Comparative Analysis by Early Clinical Stage Development, H2 2012 37
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 38
Products under Development by Companies, H2 2012 39
Products under Development by Companies, H2 2012 (Contd..1) 40
Products under Development by Companies, H2 2012 (Contd..2) 41
Products under Development by Companies, H2 2012 (Contd..3) 42
Products under Development by Companies, H2 2012 (Contd..4) 43
Products under Development by Companies, H2 2012 (Contd..5) 44
Products under Development by Companies, H2 2012 (Contd..6) 45
Products under Development by Companies, H2 2012 (Contd..7) 46
Products under Development by Companies, H2 2012 (Contd..8) 47
Products under Investigation by Universities/Institutes, H2 2012 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 60
Genzyme Corporation, H2 2012 61
Kyowa Hakko Kirin Co., Ltd., H2 2012 62
Osiris Therapeutics, Inc., H2 2012 63
Amgen Inc., H2 2012 64
Athersys, Inc., H2 2012 65
GlaxoSmithKline plc, H2 2012 66
Quark Pharmaceuticals, Inc., H2 2012 67
AbGenomics International, Inc., H2 2012 68
Emergent BioSolutions Inc., H2 2012 69
Oxford BioMedica plc, H2 2012 70
Pharming Group N.V., H2 2012 71
Albany Molecular Research, Inc., H2 2012 72
Vectura Group plc, H2 2012 73
BioLineRx, Ltd., H2 2012 74
Novartis AG, H2 2012 75
Isotechnika Pharma Inc., H2 2012 76
Astellas Pharma Inc., H2 2012 77
Pfizer Inc., H2 2012 78
Rigel Pharmaceuticals, Inc., H2 2012 79
ViroPharma Incorporated, H2 2012 80
Genmab A/S, H2 2012 81
novosom AG, H2 2012 82
Zosano Pharma, Inc., H2 2012 83
4SC AG, H2 2012 84
Celldex Therapeutics, Inc., H2 2012 85
IMMUNOMEDICS, INC, H2 2012 86
LifeCycle Pharma A/S, H2 2012 87
Circadian Technologies Limited, H2 2012 88
Cleveland BioLabs, Inc., H2 2012 89
Clinuvel Pharmaceuticals Limited, H2 2012 90
Accentia Biopharmaceuticals, Inc., H2 2012 91
La Jolla Pharmaceutical Company, H2 2012 92
Jazz Pharmaceuticals, Inc., H2 2012 93
Alexion Pharmaceuticals, Inc., H2 2012 94
Portola Pharmaceuticals, Inc., H2 2012 95
Soligenix, Inc., H2 2012 96
NeoStem, Inc., H2 2012 97
Cytomedix, Inc., H2 2012 98
JCR Pharmaceuticals Co., Ltd., H2 2012 99
Pluristem Therapeutics Inc., H2 2012 100
MediPost Co., Ltd., H2 2012 101
Proteo, Inc., H2 2012 102
Cellerant Therapeutics, Inc., H2 2012 103
Digna Biotech, S.L., H2 2012 104
Biotecnol SA, H2 2012 105
Viron Therapeutics, Inc., H2 2012 106
Pharmalink AB, H2 2012 107
Wellstat Therapeutics Corporation, H2 2012 108
Argos Therapeutics, Inc., H2 2012 109
Cytheris SA, H2 2012 110
APT Pharmaceuticals, Inc., H2 2012 111
Alder Biopharmaceuticals Inc., H2 2012 112
Gene Signal International SA., H2 2012 113
Recoly N.V., H2 2012 114
Opsona Therapeutics Ltd., H2 2012 115
TetraLogic Pharmaceuticals, H2 2012 116
Fresenius Biotech GmbH, H2 2012 117
Conatus Pharmaceuticals Inc., H2 2012 118
Angion Biomedica Corp., H2 2012 119
NovImmune SA, H2 2012 120
Lumen Therapeutics, H2 2012 121
TcL Pharma SAS, H2 2012 122
Polyphor Ltd., H2 2012 123
Omeros Corporation, H2 2012 124
Adeona Pharmaceuticals, Inc., H2 2012 125
Trillium Therapeutics Inc., H2 2012 126
iBio, Inc., H2 2012 127
Kiadis Pharma B.V., H2 2012 128
CBio Limited, H2 2012 129
Bellicum Pharmaceuticals, Inc., H2 2012 130
Sirnaomics, Inc., H2 2012 131
Limerick BioPharma, Inc., H2 2012 132
Biokine Therapeutics Ltd., H2 2012 133
KYORIN Pharmaceutical Co., Ltd., H2 2012 134
Tolera Therapeutics, Inc., H2 2012 135
Medistem, Inc., H2 2012 136
NasVax Ltd., H2 2012 137
Ikaria Inc., H2 2012 138
REGiMMUNE Corporation, H2 2012 139
ADIENNE Pharma & Biotech, H2 2012 140
TikoMed AB, H2 2012 141
Nephrx Corporation, H2 2012 142
Dr. Falk Pharma GmbH, H2 2012 143
Dompe Farmaceutici S.p.A., H2 2012 144
Amplimmune, Inc., H2 2012 145
Lycera Corp., H2 2012 146
Perseid Therapeutics LLC, H2 2012 147
ImmuneWorks, LLC, H2 2012 148
RNL BIO Co., Ltd., H2 2012 149
Icon Bioscience, Inc., H2 2012 150
Therapure Biopharma Inc., H2 2012 151
Neumedicines Inc., H2 2012 152
iTherX Pharmaceuticals Inc., H2 2012 153
Sigmoid Pharma., H2 2012 154
Biopeutics co., Ltd., H2 2012 155
Assessment by Monotherapy Products, H2 2012 156
Assessment by Combination Products, H2 2012 157
Assessment by Stage and Route of Administration, H2 2012 159
Assessment by Stage and Molecule Type, H2 2012 162
Transplantation Therapeutics – Drug Profile Updates 253
Transplantation Therapeutics – Discontinued Products 264
Transplantation Therapeutics – Discontinued Products (Contd..1) 265
Transplantation Therapeutics – Discontinued Products (Contd..2) 266
Transplantation Therapeutics – Discontinued Products (Contd..3) 267
Transplantation Therapeutics – Dormant Products 268
Transplantation Therapeutics – Dormant Products (Contd..1) 269
Transplantation Therapeutics – Dormant Products (Contd..2) 270
Transplantation Therapeutics – Dormant Products (Contd..3) 271
Transplantation Therapeutics – Dormant Products (Contd..4) 272
Transplantation Therapeutics – Dormant Products (Contd..5) 273
Transplantation Therapeutics – Dormant Products (Contd..6) 274
Transplantation Therapeutics – Dormant Products (Contd..7) 275
Transplantation Therapeutics – Dormant Products (Contd..8) 276
Transplantation Therapeutics – Dormant Products (Contd..9) 277
Transplantation Therapeutics – Dormant Products (Contd..10) 278
Transplantation Therapeutics – Dormant Products (Contd..11) 279
Transplantation Therapeutics – Dormant Products (Contd..12) 280
Transplantation Therapeutics – Dormant Products (Contd..13) 281

List of Figures
Number of Products under Development for Transplantation, H2 2012 18
Products under Development for Transplantation – Comparative Analysis, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 28
Late Stage Products, H2 2012 35
Mid Clinical Stage Products, H2 2012 36
Early Clinical Stage Products, H2 2012 37
Discovery and Pre-Clinical Stage Products, H2 2012 38
Assessment by Monotherapy Products, H2 2012 156
Assessment by Combination Products, H2 2012 157
Assessment by Route of Administration, H2 2012 158
Assessment by Stage and Route of Administration, H2 2012 159
Assessment by Molecule Type, H2 2012 160
Assessment by Stage and Molecule Type, H2 2012 161

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos